Epigenetics refers to reversible and heritable changes in genetic functions that occur without changes in DNA sequences. Epigenetic mechanisms like DNA methylation, histone modification, and microRNAs play crucial roles in gene expression and cellular differentiation. Increasing research activities aimed at understanding epigenetic mechanisms underlying various diseases as well as utilizing epigenetics for drug discovery is driving the global epigenetics market.
The global epigenetics market is estimated to be valued at US$ 14.8 Bn in 2023 and is expected to exhibit a CAGR of 7.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Rising investments in epigenetics research and development activities is one of the major trends fueling the growth of the epigenetics market. Epigenetics studies are providing novel insights into disease mechanisms and advancing drug discovery. Large pharmaceutical players are increasingly funding epigenetics research focusing on developing new therapeutic targets and customized treatment approaches. For instance, H3 Biomedicine, Inc. raised $226 million in 2021 to advance its epigenetic drug discovery platform. Similarly, large capital investments are supporting the development of advanced epigenetic technologies like next-generation sequencing platforms to accelerate epigenome-wide association studies. This significant focus on harnessing epigenetic mechanisms is expected to translate into new diagnostics and targeted therapeutics over the forecast period.
Segment Analysis
The global epigenetics market is dominated by the drug discovery and development segment. This segment is leading as epigenetic mechanisms play a crucial role in regulating gene function and expression during various biological processes such as DNA replication, cell differentiation, and embryonic development. Targeted epigenetic drug therapeutics have illustrated potential in the treatment of various diseases like cancer, diabetes, autoimmune disorders, and neurological diseases.
Key Takeaways
The Global Epigenetics Market Share is expected to witness high growth during the forecast period owing to the increasing prevalence of chronic and lifestyle diseases globally. Advancements in sequencing technologies and data analytics are further contributing to market growth. The global epigenetics market is estimated to be valued at US$ 14.8 Bn in 2023 and is expected to exhibit a CAGR of 7.2% over the forecast period 2023 to 2030.
Regional analysis
North America currently dominates the global epigenetics market due to major market players domiciled in the region, presence of advanced healthcare infrastructure, and growing R&D investments. However, Asia Pacific is projected to exhibit highest growth during the forecast period due to rising healthcare expenditure, increasing burden of chronic diseases, and growing adoption of epigenetics techniques in countries like China and India.
Key players
Key players operating in the epigenetics market are L€TMOreal S.A, Procter and Gamble Company (P&G), Estee Lauder Companies Inc., The Unilever Plc, Shiseido Co. Ltd., Johnson and Johnson Limited, Kose Corporation, and Kao Corporation. These players are focused on new product launches, partnerships, and collaborations to strengthen their market position. For instance, in 2023 L€TMOreal S.A launched an epigenetic based anti-aging skincare range using microRNA technology.
Get More Insights Here
https://www.newswirestats.com/epigenetics-market-size-share-growth-outlook-2023/
English
Arabic
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian